Compare PMT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | AMPH |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | PMT | AMPH |
|---|---|---|
| Price | $12.10 | $22.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $13.50 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 1.1M | 380.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.03 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $1.55 | $4.64 |
| P/E Ratio | $12.59 | ★ $11.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.15 | $17.03 |
| 52 Week High | $13.80 | $31.26 |
| Indicator | PMT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 62.13 |
| Support Level | $11.72 | $20.39 |
| Resistance Level | $12.15 | $23.08 |
| Average True Range (ATR) | 0.21 | 0.77 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 58.62 | 81.96 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.